Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Non-Current Assets data on file, last reported at $392000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 9.89% year-over-year to $392000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 29.06% YoY), and the FY2025 full-year result was $420000.0, down 23.91% from the prior year.
• Non-Current Assets retreated to $392000.0 in Q1 2026, from $420000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $31.2 million in Q1 2023 to a low of $151000.0 in Q3 2025.
• A 5-year average of $5.2 million and a median of $506000.0 in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 55.3% in 2023 and tumbled 98.62% in 2024, its largest moves.
• Tracing MLYS's Non-Current Assets over 5 years: stood at $1.6 million in 2022, then soared by 55.3% to $2.5 million in 2023, then plunged by 78.21% to $552000.0 in 2024, then slipped by 23.91% to $420000.0 in 2025, then fell by 6.67% to $392000.0 in 2026.
• Business Quant data shows MLYS's Non-Current Assets at $392000.0 in Q1 2026, $420000.0 in Q4 2025, and $151000.0 in Q3 2025.